Search clinical trials for: Amyloidosis, Wild Type

Total 64957 results

GlaxoSmithKline
Pfizer

Completed

A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Anti-Cancer Activity of Trametinib in Combination With Palbociclib in Subjects With Solid Tumors

Cancer

United States
Novartis Pharmaceuticals

Completed

4 Year Extension Study of Efficacy and Safety of Secukinumab in Patients With Moderate to Severe Chronic Plaque-type Psoriasis

Moderate to Severe Chronic Plaque-Type Psoriasis

United States, Germany, Japan, Bulgaria, Czechia, Singapore, Switzerland, United Kingdom, Italy, France, Vietnam, Poland, Slovakia, Austria, Canada
University of Texas Southwestern Medical Center

Completed

A Phase 1B Clinical Trial of Trametinib Plus Digoxin in Patients With Unresectable or Metastatic BRAF Wild-type Melanoma

Melanoma

United States
Merck Sharp & Dohme LLC

Completed

Immunogenicity and Safety Study of Proquad® and Infanrix® Hexa When Administered Concomitantly (V221-035)

Hepatitis B | Measles | Pertussis | Rubella | Mumps | Tetanus | Diphtheria | Varicella | Poliomyelitis | Haemophilus Infections

Germany, Italy
National Cancer Institute (NCI)

Completed

Carboplatin and Paclitaxel With or Without Viral Therapy in Treating Patients With Recurrent or Metastatic Pancreatic Cancer

Pancreatic Ductal Adenocarcinoma | Recurrent Pancreatic Carcinoma | Stage IV Pancreatic Cancer | Pancreatic Acinar Cell Carcinoma

United States
Gruppo Oncologico del Nord-Ovest

Unknown

Cetuximab Rechallenge in Irinotecan-pretreated mCRC, KRAS, NRAS and BRAF Wild-type Treated in 1st Line With Anti-EGFR Therapy (CRICKET). (CRICKET)

Metastatic Colorectal Cancer

Italy
Sinocelltech Ltd.
Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Unknown

Safety and Efficacy of Recombinant Anti-EGFR Monoclonal Antibody in Patients With Wild-type RAS and BRAF mCRC

Metastatic Colorectal Cancer

China
RenJi Hospital

Active, not recruiting

Neoadjuvant Chemotherapy Combined With Cetuximab for EGFR Wild Type Locally Advanced Rectal Cancer

Rectal Cancer Stage III

China
Yaounde Central Hospital
University of Yaounde 1; University of Buea

Completed

Short Term Effect of Liraglutide Versus Vildagliptine on Insulin Secretion and Insulin Sensitivity in Type 2 Diabetes (LIRAVIS)

Type 2 Diabetes Mellitus

Cameroon
Chong Kun Dang Pharmaceutical

Completed

A Clinical Trial to Compare Safety and Pharmacokinetic Characteristics of CKD-337

Dyslipidemias

Korea, Republic of
King Faisal Specialist Hospital & Research Center
Merck Sharp & Dohme LLC

Unknown

Grazoprevir/Elbasvir for Treatment of Hepatitis C Virus Genotype 4 Post Kidney Transplant

Hepatitis C
National Institute of Allergy and Infectious Diseases...

Withdrawn

Safety and Effectiveness of a Seasonal Live Attenuated Influenza Vaccine in a Human Challenge Model of Infection With Wild-type (wt) Influenza A/California/2009 (H1N1)-Like Virus

Influenza, Human

United States
University Hospital, Strasbourg, France
Novartis

Completed

A Prospective, Multicenter, Randomized, Open-label Study of 12 Week Duration to Evaluate the Effect of VILDagliptin Added to Insulin on Glycaemic Control in haemoDIALyzed Patients With Type 2 Diabetes: Probe Analysis of CGM

Haemodialyzed, Type 2 Diabetes

France
GlaxoSmithKline

Completed

Safety, Pharmacokinetics (PK) of AKT and MEK Combination

Cancer

United States
Yale University

Withdrawn

Cetuximab and Savolitinib Treatment of Ras Wild-Type Colorectal Cancer

Colorectal Cancer
Vanderbilt University

Completed

Treatment of Supine Hypertension in Autonomic Failure

Hypertension

United States
Groupe Hospitalier Paris Saint Joseph

Withdrawn

Phase II Study of Afatinib as Third- or Further-line Treatment for Patients With Stage IV Bronchial Adenocarcinoma, Harboring Wild-type EGFR, Expressing the Neurotensin - Neurotensin Receptor Complex (THEN)

SMALL CELL LUNG CARCINOMA

France
Lund University

Completed

DPP-4 Inhibition, Incretins and Islet Function (CODI24)

Type 2 Diabetes

Sweden
Novartis Pharmaceuticals

Completed

PKC412 in Participants With Acute Myeloid Leukemia or With Myelodysplastic Syndrome (CPKC412A2104 Core); and PKC412 in Participants With Acute Myeloid Leukemia or With Myelodysplastic Syndrome With Either Wild Type or Mutated FMS-like Tyrosine Kinase 3 (FLT3) (CPKC412A2104E1 and CPKC412A2104E2)

Acute Myeloid Leukemia | Myelodysplastic Syndromes

United States
EPS Corporation

Completed

Achievement of Improved Survival by Molecular Targeted Chemotherapy and Liver Resection for Not Optimally Resectable Colorectal Liver Metastases (ATOM)

Liver Only Metastasis From KRAS Exon 2 Wild Type (Under Protocol 1.0-1.2 Edition) and RAS Wild Type (Under Protocol 2.0 Edition) Colorectal Cancer

Japan
Novartis

Completed

A 56-Week Extension to a Clinical Study to Assess the Efficacy and Safety of Vildagliptin Compared to Placebo in Drug Naive Patients With Type 2 Diabetes and Mild Hyperglycemia

Diabetes Mellitus, Type 2

Germany
Azienda Ospedaliero-Universitaria di Parma

Completed

Effect of Vildagliptin vs. Glibenclamide on Circulating Endothelial Progenitor Cell Number Type 2 Diabetes

Type 2 Diabetes

Italy
EPS Corporation

Completed

Exploratory Study in Achievement of Improved Survival by Molecular Targeted Chemotherapy and Liver Resection for Not Optimally Resectable Colorectal Liver Metastases (ATOM ES)

Colorectal Cancer | Liver Metastasis

Japan
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Vildagliptin in Combination With Metformin in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States
Novartis

Completed

Efficacy and Safety of Combination Therapy of Vildagliptin/Metformin in Patients in Type 2 Diabetes Mellitus (T2DM)

Type 2 Diabetes Mellitus

Thailand
HiberCell, Inc.

Terminated

Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer (PRIMUS)

Colorectal Cancer

United States, Puerto Rico, Germany, France
Novartis Pharmaceuticals

Completed

Glycemic Excursions in Type 2 Diabetic Patients With Vildagliptin and Metformin Versus Vildagliptin and Glimepiride (GLOBE)

Hypoglycemia | Type 2 Diabetes

Colombia
Merck KGaA, Darmstadt, Germany
Merck Ltd., India

Terminated

An Observational Study to Evaluate the Safety and Efficacy of FOLFIRI / FOLFOX Plus Cetuximab as First-line Therapy in Patients With KRAS Wild-type Metastatic Colorectal Cancer

Colorectal Neoplasms

India
Rio de Janeiro State University
Laboratory for Clinical and Experimental Research on Vascular Biology

Completed

Acute and Short-term Chronic Effects of Galvus (Vildagliptin) in Diabetes Type 2 Obese Women

1- Microvascular Function | 2-oxidative Stress | 3-inflammation

Brazil
Merck Sharp & Dohme LLC

Completed

A Study Comparing the Pharmacokinetic and Pharmacodynamic Profiles for Sitagliptin, Saxagliptin and Vildagliptin in Participants With Type 2 Diabetes Mellitus (T2DM) (MK-0431-142)

Type 2 Diabetes Mellitus
National Cancer Institute (NCI)
University of Chicago; City of Hope Medical Center; University of Southern California and other collaborators

Completed

Randomized Phase II Study of AZD6244 (Mitogen-activated Protein Kinase Inhibitor) MEK-Inhibitor With Erlotinib in KRAS Wild Type Advanced Non-Small Cell Lung Cancer (NSCLC) and a Randomized Phase II Study of AZD6244 With Erlotinib in Mutant KRAS Adva...

Non Small Cell Lung Carcinoma

United States
Novartis

Completed

Efficacy and Safety of Three Doses of Vildagliptin in Drug Naive Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Vildagliptin in Combination With Pioglitazone in Drug Naive Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Vildagliptin Compared to Rosiglitazone in Drug Naive Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States, Germany
Massachusetts General Hospital
Dana-Farber Cancer Institute; Beth Israel Deaconess Medical Center; Amgen

Completed

Panitumumab in Cetuximab Refractory KRAS Wild-Type Colorectal Cancer

Colorectal Cancer

United States
Novartis Pharmaceuticals

Completed

Early add-on Vildagliptin in Patients With Type 2 Diabetes Inadequately Controlled by Metformin

Type-2 Diabetes Mellitus

Hong Kong
Takeda

Completed

Panitumumab for Intravenous Infusion 100 mg and 400 mg Special Drug Use Surveillance "Survey on Unresectable, Advanced or Recurrent Colorectal Cancer With Wild-type KRAS Gene" (All-patient Surveillance)

Advanced or Recurrent Colorectal Cancer
SatRx LLC

Completed

Efficacy and Safety of Gosogliptin as Monotherapy and in Combination With Metformin vs. Vildagliptin as Monotherapy and in Combination With Metformin in Drug-naive Type 2 Diabetic Patients.

Diabetes Mellitus, Type 2

Russian Federation
Amgen

Completed

Comparison of Survival Benefit of Panitumumab With Supportive Care to Best Supportive Care Alone in Patients With Metastatic Colorectal Cancer

Metastatic Colorectal Cancer

Romania, Canada, Korea, Republic of, Philippines, Lithuania, Serbia, Latvia, Estonia, Greece, India, China, Croatia, Mexico, Malaysia, Chile, Brazil
Novo Nordisk A/S

Completed

The Effect of Insulin Detemir in Combination With Liraglutide and Metformin Compared to Liraglutide and Metformin in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

United States, Italy, Puerto Rico, Spain, United Kingdom, Netherlands, Belgium, Germany, France, Canada
Novartis

Completed

Extension to a Study on the Efficacy and Safety of Vildagliptin in Combination With Glimepiride in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States
Novartis

Completed

Extension to a Study of the Efficacy and Safety of Vildagliptin in Patients With Type 2 Diabetes With Hemoglobin A1c (HbA1c) 9-11%

Diabetes Mellitus, Type 2

Switzerland
Novartis

Completed

Extension to a Study to Assess the Efficacy and Safety of Three Doses of Vildagliptin in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States
Novartis

Completed

Extension to a Study on the Efficacy and Safety of Vildagliptin in Combination With Metformin in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States
Novartis

Completed

Vildagliptin 100 mg Once Daily vs. Placebo as add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Metformin

Diabetes Mellitus, Type 2

Germany
Novartis Pharmaceuticals

Completed

Vildagliptin 50 mg Twice Daily in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin

Type 2 Diabetes Mellitus

Egypt
Novartis Pharmaceuticals

Completed

Vildagliptin Versus Liraglutide - Patient Preference After Receiving Both Medications (PREFER)

Type 2 Diabetes

Germany
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Vildagliptin as add-on Therapy to Metformin in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

Japan
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Study of Apatinib as 3rd/4th Line Treatment in Patients With Advanced Non-Squamous Non-small Cell Lung Cancer Harboring Wild-type Epidermal Growth Factor Receptor (EGFR) (ANSWER)

Carcinoma, Non-Small-Cell Lung

China
Novartis

Completed

Extension to a Study on the Efficacy and Safety of Vildagliptin in Combination With Pioglitazone in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States

3

Subscribe